Literature DB >> 20889809

Management of hyponatremia: providing treatment and avoiding harm.

Chirag Vaidya1, Warren Ho, Benjamin J Freda.   

Abstract

Hyponatremia, in its most severe form, requires urgent infusion of hypertonic saline to correct cerebral edema. However, overly rapid correction of chronic hyponatremia can cause osmotic demyelination syndrome. The authors review the treatment of hyponatremia in order to provide clinicians with a sound approach in a variety of settings in which severity, symptoms, and underlying disease states influence therapy. Also discussed is the current role of vasopressin antagonists in treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20889809     DOI: 10.3949/ccjm.77a.08051

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  14 in total

Review 1.  Management of hyponatremia.

Authors:  Jennifer Ji Young Lee; Kajiru Kilonzo; Amy Nistico; Karen Yeates
Journal:  CMAJ       Date:  2013-12-16       Impact factor: 8.262

Review 2.  Paraneoplastic syndromes associated with lung cancer.

Authors:  Nobuhiro Kanaji; Naoki Watanabe; Nobuyuki Kita; Shuji Bandoh; Akira Tadokoro; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  World J Clin Oncol       Date:  2014-08-10

3.  Efficacy of tolvaptan in patients with refractory ascites in a clinical setting.

Authors:  Takamasa Ohki; Koki Sato; Tomoharu Yamada; Mari Yamagami; Daisaku Ito; Koki Kawanishi; Kentaro Kojima; Michiharu Seki; Nobuo Toda; Kazumi Tagawa
Journal:  World J Hepatol       Date:  2015-06-28

4.  Prevalence of Hyponatremia in Elderly Patients with Hip Fractures: A Two-Year Study.

Authors:  Rocco Aicale; Domiziano Tarantino; Nicola Maffulli
Journal:  Med Princ Pract       Date:  2017-08-14       Impact factor: 1.927

Review 5.  The Efficacy and Safety of Tolvaptan in Patients with Hyponatremia: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Benlei Li; Dong Fang; Cheng Qian; Hongliang Feng; Yanggan Wang
Journal:  Clin Drug Investig       Date:  2017-04       Impact factor: 2.859

6.  Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.

Authors:  Michael J Roy; Keith A Erdman; Anura T Abeyratne; Lisa C Plumb; Kenneth Lasseter; Dennis S Riff; James J Keirns
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

7.  Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  David E Ost; Sai-Ching Jim Yeung; Lynn T Tanoue; Michael K Gould
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

8.  Effect of hypokalemia on the clinical impact of hyponatremia.

Authors:  Mohamed Osama Hegazi
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-05-03       Impact factor: 3.738

Review 9.  Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.

Authors:  Paul Gaglio; Kwaku Marfo; Joseph Chiodo
Journal:  Dig Dis Sci       Date:  2012-06-26       Impact factor: 3.199

10.  Vaptans: A new option in the management of hyponatremia.

Authors:  Suruchi Aditya; Aditya Rattan
Journal:  Int J Appl Basic Med Res       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.